Reltecimod
Description
Reltecimod (AB-103) is an antagonist of the T cell-specific surface glycoprotein CD28 (TP44). Reltecimod has good resistance effects against different bacterial infections, bacterial exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates inflammatory responses by targeting and attenuating, but not inhibiting, the critical CD28/B7-2 costimulatory pathway. Reltecimod can be used in research on necrotizing soft tissue infections (NSTIs).
Product Details
| Product Name | Reltecimod |
| Biological activity | Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs). |
| Formula | C46H72N10O15S |
| CAS Number | 1447799-33-8 |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | {d-Ala}-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-{d-Ala} |
| Sequence Shortening | {d-Ala}-SPMLVAYD-{d-Ala} |
| Storage | Sealed storage, away from moisture |
